MTAP 抗体

参考文献

1. Yuki Yabuuchi, Kenzo Hiroshima, Hisayuki Oshima, Jun Kanazawa, Kenji Hayashihara, Takayuki Nakagawa, Masaki Shimanouchi, Shingo Usui, Shuji Oh-ishi, Takefumi Saito, Nobuyuki Hizawa, Yuko Minami.Usefulness of malignant pleural effusion for early cytological diagnosis of mesothelioma in situ: A case report. Oncol Lett. 2022 Oct 25;24(6):440. doi: 10.3892/ol.2022.13560. eCollection 2022 Dec.
2. E. Olkhov-Mitsel, E. Slodkowska, M. Downes.34th European Congress of Pathology - Abstracts. Virchows Arch. 2022 Aug 16;1-364. doi: 10.1007/s00428-022-03379-4. Online ahead of print.
3. Keisuke Goto, Kohei Ogawa, Tsunekazu Hishima, Naoki Oishi, Ozumi Tomita, Takuji Tsuyuki, Takao Oda, Yoshifumi Iwahashi, Yutaka Inaba, Keiichiro Honma.Seborrheic Keratosis With Malignant Transformation (Invasive or Noninvasive Squamous Cell Carcinoma Arising in Seborrheic Keratosis): A Clinicopathologic and Immunohistochemical Study of 11 Cases. Am J Dermatopathol. 2022 Dec 1;44(12):891-899. doi: 10.1097/DAD.0000000000002245. Epub 2022 Jul 6.
4. Luka Brcic, Nolwenn Le Stang, Florian Gallob, Daniel Pissaloux, Ruth Sequeiros, Sandrine Paindavoine, Jean Claude Pairon, Marie Karanian, Sanja Dacic, Nicolas Girard, Andrew Churg, Franck Tirode, Francoise Galateau-Salle. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas Arch Pathol Lab Med. 2022 Jun 23. doi: 10.5858/arpa.2021-0331-OA. Online ahead of print.
5. Dean A Fennell, Amy King, Seid Mohammed, Alastair Greystoke, Sarah Anthony, Charlotte Poile, Nada Nusrat, Molly Scotland, Vina Bhundia, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Amrita Bajaj, Cathy Richards, Peter Wells-Jordan, Anne Thomas, MiST2 study group. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Lancet Oncol. 2022 Mar;23(3):374-381. doi: 10.1016/S1470-2045(22)00062-6. Epub 2022 Feb 11.
6. Megumi Nishikubo, Naoe Jimbo, Yugo Tanaka, Motoko Tachihara, Tomoo Itoh, Yoshimasa Maniwa.Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma? Virchows Arch. 2022 Aug;481(2):307-312. doi: 10.1007/s00428-022-03281-z. Epub 2022 Jan 19.
7. Shoh Sasaki, Maiko Takeda, Takanori Hirose, Tomomi Fujii, Hiroe Itami, Tomoko Uchiyama, Kohei Morita, Ryosuke Matsuda, Shuichi Yamada, Ichiro Nakagawa, Chiho Ohbayashi. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study. J Neuropathol Exp Neurol. 2022 Jan 29;81(2):117-126. doi: 10.1093/jnen/nlab127.
8. Simone Terra, Anja C Roden, Eunhee S Yi, Marie Christine Aubry, Jennifer M Boland. Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma. Am J Clin Pathol. 2022 Jan 6;157(1):33-39. doi: 10.1093/ajcp/aqab091.
9. Toshiaki Kawa, Reishi Seki, Kuniharu Miyajima, Hiroshi Nakashima, Takayuki Takeda, Tomoyuki Murakami, Keisuke Aoe, Kazunori Okabe,Keiichi Homma, Yoshitane Tsukamoto, Koichi Sunada, Yasuhiro Terasaki, Maki Iida, Hideki Orikasa, Kenzo Hiroshima.Malignant pleural mesothelioma with heterologous elements. J Clin Pathol. 2021 Aug 10;jclinpath-2021-207575. doi: 10.1136/jclinpath-2021-207575. Online ahead of print.
10. Taylor Salisbury, Andrew Churg.CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations. Virchows Arch. 2021 Nov;479(5):1047-1050. doi: 10.1007/s00428-021-03077-7. Epub 2021 Mar 15.
11. Yoshiaki Kinoshita, Makoto Hamasaki, Shinji Matsumoto, Masayo Yoshimura, Ayuko Sato, Tohru Tsujimura, Toshiaki Kamei, Kunimitsu Kawahara, Akinori Iwasaki, Kazuki Nabeshima.Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma. Cancer Cytopathol. 2021 Jul;129(7):526-536. doi: 10.1002/cncy.22409. Epub 2021 Jan 25.
12. No authors listed.Abstracts : 32 nd Congress of the ESP and XXXIII International Congress of the IAP. Virchows Arch. 2020 Dec;477(Suppl 1):1-390. doi: 10.1007/s00428-020-02938-x.
13. Kaishi Satomi, Makoto Ohno, Yuko Matsushita, Masamichi Takahashi, Yasuji Miyakita, Yoshitaka Narita, Koichi Ichimura, Akihiko Yoshida.Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. Mod Pathol. 2021 Apr;34(4):688-700. doi: 10.1038/s41379-020-00701-w. Epub 2020 Oct 19.
14. He Zhen Ren, Simon Cheung, Andrew Churg.c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations. Hum Pathol. 2020 Nov;105:31-36. doi: 10.1016/j.humpath.2020.08.010. Epub 2020 Sep 8.
15. Yoshiaki Kinoshita, Makoto Hamasaki, Shinji Matsumoto, Masayo Yoshimura, Ayuko Sato, Tohru Tsujimura, Toshiaki Kamei, Kunimitsu Kawahara, Kazuki Nabeshima.Genomic-based Ancillary Assays Offer Improved Diagnostic Yield of Effusion Cytology With Potential Challenges in Malignant Pleural Mesothelioma. Pathol Int. 2020 Sep;70(9):671-679. doi: 10.1111/pin.12973. Epub 2020 Jun 15.
16. Berg KB, Churg AM, Cheung S, Dacic S.Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens. Cancer Cytopathol. 2019 Dec 10. doi: 10.1002/cncy.22221. [Epub ahead of print]
17. Minami K, Jimbo N, Tanaka Y, Hokka D, Miyamoto Y, Itoh T, Maniwa Y.Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report. Virchows Arch. 2020 Mar;476(3):469-473. doi: 10.1007/s00428-019-02674-x. Epub 2019 Oct 30.
18. Konishi M, Kanyama T, Maeno K, Miyagawa C, Minamiguchi S, Katsushima H, Shimada T.Detection of Anaplastic Lymphoma Kinase-Rearranged Mesothelioma Cells in Ascites by Companion Diagnostics. Acta Cytol. 2020;64(4):378-385. doi: 10.1159/000503663. Epub 2019 Oct 29.
19. Brich S, Bozzi F, Perrone F, Tamborini E, Cabras AD, Deraco M, Stacchiotti S, Dagrada GP, Pilotti S.Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. Mod Pathol. 2019 Sep 30. doi: 10.1038/s41379-019-0371-0. [Epub ahead of print]
20. Churg A, Galateau-Salle F, Roden AC, Attanoos R, von der Thusen JH, Tsao MS, Chang N, De Perrot M, Dacic S.Malignant mesothelioma in situ: morphologic features and clinical outcome. Mod Pathol. 2019 Aug 2. [Epub ahead of print]
21. Chapel DB, Schulte JJ, Berg K, Churg A, Dacic S, Fitzpatrick C, Galateau-Salle F, Hiroshima K, Krausz T, Le Stang N, McGregor S, Nabeshima K, Husain AN.MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma. Mod Pathol. 2019 Jun 23. doi: 10.1038/s41379-019-0310-0. [Epub ahead of print]
22. Kinoshita Y, Hamasaki M, Yoshimura M, Matsumoto S, Iwasaki A, Nabeshima K.Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma. Mod Pathol. 2019 Jun 23. [Epub ahead of print]
23. Berg KB, Dacic S, Miller C, Cheung S, Churg A.Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas. Arch Pathol Lab Med. 2018 Dec;142(12):1549-1553. doi: 10.5858/arpa.2018-0273-OA. Epub 2018 Jul 30.
24. Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, Wang G, Vega Y Saenz de Miera EC, Medicherla R, Christos PJ, Shapiro RL, Pavlick AC, Darvishian F, Zavadil J, Polsky D, Hernando E, Ostrer H, Osman I.Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res. 2011 Feb 22. [Epub ahead of print]